Introduction
The tumour suppressor protein p53 plays a central role in the cellular processes involved in the response to DNA damage (reviewed by Kastan et al., 1995) . p53 is made up of four domains, an N-terminal transactivation domain, a central sequence speci®c DNA binding domain and C-terminal oligomerization and regulatory domains. p53 is mutated in about half of all human tumours and the majority of mutations have been found in the DNA binding domain. However, this central area of p53 has been more extensively investigated for mutations than either the N-or Ctermini, therefore the frequency of mutations outside of the core domain may be higher than is thought (Casey et al., 1996) .
Recently two studies have reported germline mutations in members of Li ± Fraumeni (LFS) or Li ± Fraumeni like (LFL) families which aect the oligomerization domain of p53 (Lomax et al., 1997; Varley et al., 1996) . LFS was ®rst described by Li and Fraumeni (1969) and is a dominantly inherited syndrome in which aected individuals exhibit multiple primary neoplasms in childhood and early adulthood. Following early studies by Malkin and colleagues (1990) it is now established that germline p53 mutations are associated with LFS.
Members of the family which was the subject of study by Varley and co-workers (1996) had high levels of p53 in malignant and normal tissues and a mutation in the p53 gene was found at codon 344, resulting in a leucine to proline substitution. PepPlot analysis predicted the resulting p53 protein to be disrupted. In patient 904005, the proband studied by Lomax and colleagues (1997) and Barnes et al. (1992) , a point mutation resulting in the substitution of cysteine for arginine at codon 337 was discovered. Patient 904005 also exhibited high levels of p53 protein in both normal and malignant tissue and, in addition, this patient had elevated levels of MDM2 in normal tissues (Picksley et al., 1996) . MDM2 can be induced by p53 (Barak et al., 1993) and also serves as a negative regulator of p53 by directing its degradation via the ubiquitin pathway (Haupt et al., 1997; Kubbutat et al., 1997) .
There has been disagreement as to whether point mutations aecting the oligomerization domain can result in a dysfunctional p53 protein (Soussi and May, 1996) . Ishioka and co-workers (1995) demonstrated that some point mutations occurring within the oligomerization domain of p53 were inactive for certain functions of p53. However, each mutated protein was not inactive for all the functions of p53 tested (transactivation of a target gene, growth arrest and inhibition of cell growth). The present study was designed to determine if the two germline mutations aecting the oligomerization domain of p53 resulted in non-functional proteins and to assess their role in tumorigenesis.
determine the oligomerization status of the two recombinant proteins.
The proteins, in solution, were added to a twofold serial dilution of glutaraldehyde, over 11 concentrations, from 0.2 ± 0%. The glutaraldehyde cross links the oligomers of p53, the extent of cross-linking being proportional to the concentration of glutaraldehyde. The cross-linked p53 proteins were run on a SDSpolyacrylamide gel and immunoblotted. Figure 1 shows, as expected, that wild-type p53 can form tetramers. p53 344 Leu to Pro (344P) protein is unable to oligomerize to any degree and exists solely as monomers. p53 337 Arg to Cys (337C) protein can form tetramers and all the intermediates, trimers, dimers and monomers, are present. However, the oligomerization of 337C is subtly dierent from wildtype p53 as the intermediates can be demonstrated over a wider range of glutaraldehyde concentrations with wild-type p53 protein than with 337C. This may be indicative of an alteration in the equilibrium of the tetramer/dimer states.
Determination of DNA binding
One of the important functions of p53 is to transcriptionally transactivate target genes by binding to a consensus sequence. The ability of the two recombinant mutant p53 proteins to bind to the 20-mer p53 consensus DNA binding site, PG (El-Deiry et al., 1992; Hupp et al., 1992) was determined by electrophoretic mobility shift assay (EMSA). Recombinant p53 proteins purifed from E. coli are unable to bind to DNA due to the absence of post-translational modi®cations. The monoclonal antibody PAb421 is able to activate p53 to bind to DNA by binding to the C-terminal regulatory domain of p53 (Hupp et al., Figure 1 Western blots of glutaraldehyde cross-linked wild-type and mutant p53 proteins, demonstrating oligomerization of the p53 proteins. p53 protein was mixed with decreasing concentrations of glutaraldehyde, from 0.2 ± 0% over 11 concentrations, and then run on 8% SDS-polyacryalmide gel and immunoblotted using DO-1 to probe the blot. (a) wild-type p53, (b) 337C, (c) 344P
Figure 2 EMSA to demonstrate DNA binding of wild-type and mutant p53 proteins. The 20-mer p53 consensus DNA binding site, PG was used as the DNA probe. PAb421 antibody was added to the reactions to activate the recombinant p53 proteins. +: with PAb421 antibody, 7: without PAb421 antibody. Arrow points to retarded band containing p53 protein and DNA p53 oligomerization mutations in LFS/LFL families ME Lomax et al 1992). In the presence of PAb421 antibody both wildtype p53 and 337C protein can bind DNA with a similar eciency (Figure 2 ). However, 344P cannot bind to DNA in a sequence speci®c manner even with the addition of PAb421 antibody (Figure 2 ).
Induction of apoptosis
Wild-type p53 protein can induce apoptosis of the p53 null cell line Saos-2. The ability of the mutant p53 proteins, 337C and 344P, to induce apoptosis was compared to wild-type. Two additional mutated p53 proteins were also compared to wild-type protein, 337 Arg to His (337H) and 248 Arg to Gln (248Q). The 248Q mutation is in the core DNA binding domain of p53 and thus renders the protein defective for DNA binding. The 337H mutation is believed to be a silent mutation as it results in white colonies in the FASAY (a yeast based functional assay in which wild-type p53 results in white yeast colonies and mutant p53 results in red yeast colonies; (Flaman et al., 1995) ). pC53-SN3 (an expression plasmid containing wildtype p53) and the mutant derivatives were transfected into Saos-2 cells and 72 h later the extent of apoptosis was assessed as the sub-G1 peak on a DNA histogram (Ormerod et al., 1992) . In addition to staining DNA, p53 protein was also stained and therefore the percentage of p53 positive cells was known. The level of apoptosis in both the p53 positive and the p53 negative populations was determined and thus the percentage increase of apoptosis due to p53 expression could be calculated. The extent of wild-type p53 induced apoptosis was expressed as 100% and the extent of apoptosis induced by the mutant p53 proteins was expressed as a percentage of wild-type p53 induced apoptosis. Figure 3 and Table 1 show that 248Q protein induced apoptosis to 21% the level of wild-type. 344P protein induced apoptosis in Saos-2 cells to a similar level as 248Q protein, 17% the level of wild-type. In contrast, 337C protein induced apoptosis to 64% of the levels of wild-type p53 protein, which was signi®cantly dierent from both wild-type p53 and 248Q and 344P proteins (Table 1) . Apoptosis was con®rmed morphologically by¯uorescent microscopy, where condensed chromatin, fragmented nuclei and membrane blebbing were clearly visible (data not shown).
Transactivational activity
The transcriptional transactivational activity of the p53 mutants was assessed using a luciferase reporter gene driven by the bax promoter. Miyashita and colleagues (1994) demonstrated that p53 could induce Bax and in 1995 Miyashita and Reed showed that the bax promoter contains a p53 response element. pC53-SN3 or the mutant derivatives and PGL3(bax), the luciferase reporter construct, were co-transfected into Saos-2 cells and 60 h later the luciferase activity was assessed. The luciferase activity produced as a result of wild-type p53 protein transactivational activity was expressed as 100% and the luciferase activities produced by the mutated proteins were expressed as a percentage of the wild-type activity.
The transactivational activity of 337H protein was similar to that of wild-type p53 (data not shown). All the remaining mutant proteins showed transactivational activities which were signi®cantly dierent from wild-type p53 protein ( Figure 4 and Table 2 ). The transactivational activity of 248Q was 4% of wild-type and 344P protein had 11% transactivational activity of wild-type p53. 337C protein retained 60% transactivational activity of wild-type p53.
The transcriptional transactivational activity of the mutated p53 proteins was also studied in the FASAY, a yeast based assay to determine the functional status of p53. In this assay the ability of p53 to transactivate a target gene by binding to the RGC consensus sequence (Kern et al., 1991) is measured (Flaman et al., 1995) . In the FASAY wild-type p53 cDNA results in white yeast colonies and mutant p53 results in red colonies. 344P cDNA produced red yeast colonies (data not shown) further emphasizing the inability of this mutation to result in a protein with transactivational activity. 337C cDNA, however, formed pink yeast colonies (Lomax et al., 1997) consistent with the ®nding that this mutant p53 protein does have transactivational activity but at a reduced level compared to wild-type p53 protein. Figure 3 The ability of wild-type p53 and mutant proteins 248Q, 344P and 337C to induce apoptosis were compared. pC53-SN3 and the mutant derivatives were transfected into Saos-2 cells and 72 h later the extent of apoptosis was assessed as the sub-G1 peak on a DNA histogram. The dierence in apoptosis between the p53 positive and negative populations was calculated in each case and expressed as a percentage of wild-type, which was normalised to 100%. The ®gures are a mean value for ®ve replicates. WT: wild-type. For statistical analysis see Table 1 p53 oligomerization mutations in LFS/LFL families ME Lomax et al
Inhibition of Saos-2 growth
Wild-type p53 protein is capable of inhibiting the growth of Saos-2 cells and this was determined in a colony forming assay. pC53-SN3 and the mutant derivatives were transfected into Saos-2 cells and 48 h after transfection the medium on the cells was replaced with medium containing G418. The cells were incubated at 378C for 4 weeks and the number of colonies that had grown during this time was counted. As controls pC53-SN3 with no p53 gene insert (empty vector) and no DNA were transfected into Saos-2 cells. The number of colonies formed when cells were transfected with empty vector was expressed as 100%. Figure 5 illustrates the number of colonies obtained when the cells were transfected with pC53-SN3 and the mutant derivatives. Wild-type p53 protein resulted in only 5% of the number of colonies formed from empty vector. 344P protein produced 85% of the number of colonies formed by empty vector, which was not signi®cantly dierent. However, the number of colonies formed as a result of transfecting wild-type p53 protein in to Saos-2 cells is signi®cantly dierent from the number formed by transfecting 344P. 337C protein resulted in only 37% of the number of colonies of the empty vector, which is also signi®cantly dierent from the number of colonies produced from transfecting wild-type p53 protein in to Saos-2 cells. This result is consistent with both the induction of apoptosis and the transcriptional transactivation of these two mutant p53 proteins in that 344P has only a minimal, background level of activity but 337C has approximately 60% of the activity of wild-type p53 protein.
Binding to MDM2
Marston and colleagues (1995) demonstrated that tetramerization was important for p53 to bind to MDM2, therefore the ability for the mutant proteins to bind to MDM2 was determined. Relative concentrations of wild-type p53, 337C and 344P recombinant proteins were determined by immunoblotting using the p53 speci®c antibody DO12. DO12 was chosen to determine the relative concentrations of the three proteins as it is not a conformation dependent antibody, therefore any changes in the ability of the mutant proteins to bind to other proteins will not be measured and true values of relative concentrations will be obtained.
The N-terminus of MDM2, which contains the p53 binding domain (Oliner et al., 1993) , tagged to glutathione-S-transferase (GST) was bound to glutathione-sepharose beads and approximately equal amounts of wild-type p53, 337C and 344P proteins were added. Following incubation on ice to allow the p53 and MDM2 proteins to bind, the beads were washed and then run on a 10% SDS-polyacrylamide gel and the proteins were immunoblotted with DO12 antibody. Figure 6 shows that wild-type p53 protein could bind to MDM2 in this assay. The ability of 344P protein to bind to MDM2 was reduced, compared to wild-type protein and the ability of 337C to bind MDM2 was even further reduced. Image analysis demonstrated that 337C protein bound to MDM2 Figure 4 The ability of wild-type p53 and the mutant proteins 248Q, 344P and 337C to activate transcription from a luciferase reporter gene driven by the bax promoter was assessed. pC53-SN3 or the mutant derivatives and PGL3(bax), the luciferase reporter construct, were co-transfected into Saos-2 cells and 60 h later the luciferase activity was assessed. In each case the transactivational activity was expressed as a percentage of wild-type, which was normalised to 100%. The ®gures are a mean value for at least eight replicates. WT: wild-type. For statistical analysis see Table 2 Figure 5 The ability of wild-type p53 and the mutant proteins 248Q, 344P and 337C to inhibit Saos-2 cell growth was determined in a colony forming assay. The p53 proteins were compared to the controls, empty pC53-SN3 vector and no DNA. pC53-SN3 and the mutant derivatives were transfected into Saos-2 cells and 48 h after transfection the medium on the cells was replaced with medium containing G418. The cells were incubated at 378C for 4 weeks and the number of colonies that had grown during this time were counted. The ®gures are a mean value for at least ®ve replicates. WT: wild-type. For statistical analysis see Table 3 p53 oligomerization mutations in LFS/LFL families ME Lomax et al with &6% the eciency of wild-type protein and 344P bound to MDM2 with &42% the eciency of wildtype p53.
Discussion p53 acts as a transcriptional transactivator to upregulate genes involved in growth arrest and apoptosis. The p53 protein functions as a tetramer and the present study was designed to establish whether two germline mutations aecting the oligomerization domain of p53 disrupted the normal function of this protein.
344P protein was eectively non-functional in that it could only induce apoptosis in Saos-2 cells at 17% of wild-type p53 levels, it only had 11% of the transactivational activity of wild-type p53 protein and it inhibited Saos-2 cell growth with only 16% of the ability of wild-type p53. None of these activities were signi®cantly dierent from the core DNA binding mutation, 248Q (except in the inhibition of growth assay where 248Q protein appeared to have some gain of function activity). In contrast, 337C protein retained partial activity of wild-type p53 protein, transactivating luciferase from a bax promoter at 60% eciency of wild-type protein, inducing apoptosis at 64% of wildtype levels and inhibiting the growth of Saos-2 cell at 73% the ability of wild-type p53. In addition, 337C cDNA resulted in the intermediately coloured pink yeast colonies in the FASAY but 344P cDNA produced only red colonies. Again, this demonstrates that 337C protein has partial transactivational activity but 344P protein has none.
Consistent with the functional studies, 344P protein was demonstrated to exist solely as monomers and to be incapable of binding to DNA. However, 337C could form tetramers and could bind to DNA. The tetramers formed by 337C protein are not completely normal as can be seen by comparing the glutaraldehyde crosslinked wild-type p53 and 337C proteins. In addition, Davison et al. showed by biophysical assays that the tetramers formed by 337C dier considerably in their stability from wild-type p53 tetramers.
Although it has been established that deletions in the oligomerization domain can produce non-functional p53 proteins, the role of point mutations in this area is less well understood. Waterman and colleagues (1995) demonstrated that certain single point mutations in the oligomerization domain resulted in a protein which could not bind to DNA and this was dependent not only on the position of the residue which was mutated but also on the amino acid substitution. More often double or triple point amino acid substitutions were required to disrupt the function of p53 protein. The present study has demonstrated that single point mutations substituting arginine with cysteine at codon 337 and leucine with proline at codon 344 can be disruptive. However, substituting argine with histidine at codon 337 does not result in a non-functional protein. In the case of 344P the protein is as dysfunctional as the core DNA binding domain mutation, 248Q. 337C protein does retain more than half of the activity of wild-type p53 protein. This modest reduction in activity appears to be enough to result in tumorigenesis as this mutation was isolated from a LFL family member, in which no other p53 gene mutation could be found. The severity of disease in this family was no dierent from that of the family aected by the 344P mutation Varley et al., 1996) . Further, another LFS family has been identi®ed in which the only p53 mutation was a codon 337 arginine to cysteine substitution (Garber, personal communication) and, in addition, this mutation has been identi®ed in a number of sporadic tumours (Hainaut et al., 1997) . It is interesting that even though the 344P gene mutation is more disabling than the 337C mutation it has not been reported to occur in any other LFS or LFL family nor in any sporadic tumours.
The occurrence of germline p53 mutations in the oligomerization domain of two completely separate families raises the possibility that p53 mutations may be more widely spread throughout the gene than is currently accepted. The family aected by the 337C mutation was originally reported not to have a mutation in p53 . Closer examination of the gene revealed a point mutation in an area unconventional for point mutations (Lomax et al., 1997) . Casey and co-workers (1996) raise the possibility that the frequency of mutations in areas outside of the central DNA binding domain is much higher than reported but that such mutations are missed due to the restriction of investigations to exons 5 ± 8. In 1994 Birch (1994) reported the frequency of p53 mutations in LFS families to be 50%. Since then Varley and co-workers have extended their search to include exons 1 to 11, splice junctions and the promoter region of p53. Due to the more thorough investigations the frequency of Figure 6 Immunoprecipitation of p53 by the N-terminus of MDM2. GST-tagged N-terminus of MDM2 (GST-N-MDM2) was bound to glutathione beads and wild-type p53, 344P or 337C was added. Following 40 min incubation on ice the beads were washed and then run on 10% SDS-polyacryalmide gel and immunoblotted using DO12 antibody to probe the blot. WT: wild-type p53 oligomerization mutations in LFS/LFL families ME Lomax et al p53 mutations in LFS families has risen to 70% . In addition to high levels of p53 protein in normal tissue, family members of the 337C family also exhibit elevated levels of MDM2 protein (Picksley et al., 1996) . In 1993 it was established that MDM2 and p53 form a negative feedback loop in which p53 protein upregulates transcription of mdm2 and MDM2 protein results in the decreased activity of p53 protein (Wu et al., 1993) . Recently two studies have shown that MDM2 down regulates p53 levels by directing its degradation via the ubiquitin pathway (Haupt et al., 1997; Kubbutat et al., 1997) . These studies also show that binding of p53 and MDM2 is necessary for the directed degradation of p53. Therefore elevated levels of p53 protein seen in many tumours could be the result of the lack of degradation by MDM2. This is usually due to the absence of MDM2, as the majority of p53 mutations do not have transactivational activity and thus cannot upregulate MDM2 (Lane and Hall, 1997; Midgley and Lane, 1997) . The 337C protein retains signi®cant activity for transcriptional transactivation and therefore can upregulate MDM2, which could explain the high levels of MDM2 present in the tissue of family members. 337C protein, however, appears to bind ineciently to MDM2 and thus MDM2 may not be capable of directing the degradation of the mutant protein and thus p53 protein levels remain elevated.
These results indicate that single point mutations in the oligomerization domain of p53 can play a role in tumorigenesis. This study also demonstrates the value of LFS and LFL families as models for the further understanding of the biological and biochemical properties of the p53 tumour suppressor gene. Mutations aecting the p53 gene in LFS and LFL families are naturally occurring mutations, thus pinpointing which residues and which amino acid substitutions are important for the proper function of p53. In addition this study has further emphasised the importance of investigating the whole of the p53 gene for mutations as mutations outside of the central DNA binding domain occur in sporadic tumours and not only in LFS or LFL families.
Materials and methods

Site-directed mutagenesis
The p53 gene in the expression plasmids T7-7Hup53 and pC53-SN3 (Baker et al., 1990) was speci®cally mutated using a Transformer 2 SiteDirected Mutagenesis Kit (second version; Clontech Laboratories Inc.) according to the manufacturer's protocol to create 337H, 337C and 344P mutations. The p53 gene in pC53-SN3 was sub-cloned into pUC19 for mutation, by cutting out the gene with BamHI and ligating into the BamHI site of the multiple cloning site of pUC19, using standard molecular biology techniques. The mutator primers used were, 337 Arg to His GGGCGTGAGCACTTCGAGATGT, 337 Arg to Cys GGGCGTGAGTGCTTCGAGATGT and 344 Leu to Pro TTCCGAGAGCCGAATGAGGCCT. The selection primer for T7-7Hup53 was HindIII to HindIIIX CCTG-CAGCCCTAGCTTATCGAT and for pUC19 was NdeI to NdeIX GAGTGCACCATGGGCGGTGTGAAAT.
Puri®cation of recombinant p53 proteins
Recombinant wild-type p53, 337C and 344P proteins were puri®ed from E. coli as described by Midgley and colleagues (1992) .
Cell culture
Saos-2 cells were derived from an osteosarcoma and are null for p53 (Masuda et al., 1987) . The cells were routinely cultured in DMEM supplemented with 20% foetal bovine serum.
Functional analysis for the separation of alelles in yeast (FASAY)
FASAY was performed on wild-type p53, 337H, 337C and 344P containing plasmids as previously described (Flaman et al., 1995; Lomax et al., 1997) .
Glutaraldehyde cross-linking of p53 proteins
Recombinant wild-type p53, p53 337C and 344P proteins were mixed with serial twofold dilutions of glutaraldehyde, from 0.2 ± 0%, in a total volume of 20 ml and run on a 8% SDS-polyacrylamide gel. The proteins were Western blotted and probed with DO-1 antibody followed by HIP-conjugated mouse immunoglobulins. The proteins were visualized using enhanced chemiluminescence (Amersham).
Electrophoretic mobility shift assay (EMSA)
EMSA was performed with recombinant wild-type p53, 337C and 344P proteins as described by Hupp and coworkers (1992) . The DNA sequence used in the EMSA was the 20-mer p53 consensus DNA binding site, PG (El-Deiry et al., 1992) and was end-labelled with 32 P-g-ATP.
Induction of apoptosis
Saos-2 cells were transfected with 20 mg pC53-SN3 or the mutant derivatives by the calcium phosphate method using ProFection 1 Mammalian Transfection System Calcium Phosphate (Promega, Madison, USA). Seventy-two hours after transfection the cells were ®xed in ice cold 70% v/v ethanol and stained with DO-1 antibody followed by FITC-conjugated mouse immunoglobulins. Cells were counter stained with propidium iodide (PI) and analysed using a FACSCalibur¯ow cytometer (Becton Dickinson, Oxfordshire) and Cellquest software. p53 protein levels were determined by measurement of green¯uorescence and DNA content was determined by measurement of red uorescence. The extent of apoptosis was measured as the sub-G 1 peak on a DNA histogram as described previously (Ormerod et al., 1992) .
Fluorescent microscopy
Following¯ow cytometric analysis cells were centrifuged and the supernatant (PI) was removed. The cells were resuspended in the residual PI and mounted onto microscope slides. The cells were viewed on a¯uorescent microscope (Zeiss, Welwyn Garden City, UK) and the morphological characteristics of both the p53 positive and the p53 negative cells were assessed.
Transactivation of luciferase reporter gene
Saos-2 cells were co-transfected with 1 mg pC53-SN3 or the mutant derivatives and 2 mg PGL3(bax) by the calcium phosphate method. PGL3(bax) is a luciferase reporter gene (Promega) in which the luciferase gene is driven by a p53 oligomerization mutations in LFS/LFL families ME Lomax et al 370 bp fragment of the bax promoter. Sixty hours after transfection luciferase activity was measured using the Luciferase Assay System (Promega), according to the manufacturer's protocol, and a LKB-Wallac 1251 Luminometer (BioOrbit, Turku, Finland).
Inhibition of cell growth
Saos-2 cells were transfected with 7 mg of pC53-SN3 (which carries the selection marker for neomycin resistance) or the mutant derivatives by the calcium phosphate method. Forty-eight hours following transfection routine culture medium was replaced with medium containing G418 at 1 mg/ml. The cells were maintained in this medium for three weeks and then the number of colonies were counted.
Immunoprecipitation of p53 by MDM2
Glutathione-sepharose beads, the N-terminus of mdm2 linked to glutathione-S-transferase (GST) and recombinant wild-type p53, 337C and 344P proteins were mixed together and incubated on ice for 40 min. The beads were washed alternatively with 1.26PBS/1% Triton X-100 and distilled water three times and then run on a 10% SDSpolyacrylamide gel. The proteins were Western blotted and probed with DO-1 antibody followed by HIPconjugated mouse immunoglobulins. The proteins were visualized using enhanced chemiluminescence (Amersham).
